FDA Investigating Risk of Pancreatitis in Type 2 Diabetes Meds
The US Food and Drug Administration (FDA) is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis, or inflammation of the pancreas, and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with a class of drugs called incretin mimetics.
New Diabetes Rx Delivers Results
While several medications are already on the market to treat diabetes, not all patients have the desired control over their blood sugar levels. Alogliptin may offer a fresh option.